Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
26 May 2021 - 9:00PM
Business Wire
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage
precision medicine company developing innovative treatments for
genetically defined age-related macular degeneration (AMD), today
announced that Jason Meyenburg, Chief Executive Officer of Gemini
Therapeutics, is scheduled to participate virtually in the
Jefferies Virtual Healthcare Conference on Wednesday, June 2 at
3:30 PM ET.
A live webcast of the event will be available on the "Events
& Presentations" page on the Company's website. A replay of the
webcast will be archived on the Company's website for 30 days
following the presentation.
About Gemini Therapeutics
Gemini Therapeutics is a clinical stage precision medicine
company developing novel therapeutic compounds to treat genetically
defined age-related macular degeneration (AMD). Gemini’s lead
candidate, GEM103, is a recombinant form of human complement factor
H protein (CFH) and is designed to address both complement
hyperactivity and restore retinal health in patients with AMD.
GEM103 is currently in a Phase 2a trial in dry AMD patients with a
CFH risk variant and a Phase 1/2a study in patients with
neovascular age-related macular degeneration with or at risk for
macular atrophy. The company has generated a rich pipeline
including recombinant proteins, gene therapies, and monoclonal
antibodies and is advancing a potentiating antibody for CFH,
GEM307, into clinical development for treatment of systemic
diseases.
For more information, visit www.geminitherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210526005186/en/
Gemini Investor Contact: Argot Partners Sherri Spear
212-600-1902 gemini@argotpartners.com Gemini Media Contact:
Argot Partners Joshua Mansbach 212-600-1902
gemini@argotpartners.com
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Apr 2024 to May 2024
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Gemini Therapeutics Inc (NASDAQ): 0 recent articles
More Gemini Therapeutics Inc News Articles